1 / 11

MONET - Trial Design

The MONET trial 96 week analysis: darunavir/r monotherapy versus darunavir/r + 2NRTIs, for patients with HIV RNA < 50 copies/mL at baseline. Armin Rieger, Denes Banhegyi, Wolfgang Schmidt, Jose Arribas, Andrew Hill, Yvonne Van Delft, Christiane Moecklinghoff

alyson
Download Presentation

MONET - Trial Design

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The MONET trial 96 week analysis: darunavir/r monotherapy versus darunavir/r + 2NRTIs, for patients with HIV RNA < 50 copies/mL at baseline Armin Rieger, Denes Banhegyi, Wolfgang Schmidt, Jose Arribas, Andrew Hill, Yvonne Van Delft, Christiane Moecklinghoff Presented at World AIDS Conference, Vienna, Austria, 22nd July 2010 Abstract TBLBB209

  2. MONET - Trial Design • Inclusion: Taking 2 NRTI + either NNRTI or boosted PI at screening (stratified) • HIV RNA <50 copies/mL for at least 6 months, no prior use of darunavir (DRV) • No history of virological failure DRV/r 800/100 mg OD + 2 NRTI (re-optimised at baseline) n = 129 256 subjects DRV/r 800/100 mg OD n = 127 144 weeks Primary Endpoint: failure at week 48 (TLOVR). Per Protocol, Switch = Failure The Week 96 analysis was a secondary endpoint. Rieger et al. WAC July 2010, Vienna [abstr TBLBB209]

  3. MONET: statistical methods for HIV RNA analysis Main efficacy endpoint: TLOVR, switch equals failure analysis If a patient shows a confirmed elevation in HIV RNA >50 copies/mL at two visits, this is a failure, even if the HIV RNA is then suppressed <50 copies/mL at Week 96.Stopping DRV/r in either arm, or adding NRTIs in the monotherapy arm is also a failure. Missing data is failure. Secondary endpoint: Switch included analysis This analysis only includes the HIV RNA levels at Week 96. If HIV RNA is re-suppressed at Week 96 following an earlier elevation, this is counted as success. Changes in treatment are permitted. Missing data is failure. All results were consistent between the ITT and Per Protocol populations. ITT analysis is shown here. Rieger et al. WAC July 2010, Vienna [abstr TBLBB209]

  4. MONET: Baseline Characteristics (ITT) Age, years (median, range) Male (%) Caucasian (%) 43 (24-72) 83% 90% 43 (25-67) 78% 92% 579 12% 6.4 (4.0) 57% 43% 48% 28% 0 15 (12%) 12 (9%) 571 14% 7.4 (4.2) 56% 44% 35% 23% 0 24 (19%) 20 (16%) Disease characteristics CD4 count (median (range), cells/uL) CD4 <350 cells/uL (%) Duration of prior ARVs, years (mean, sd) Use of PI at screening (%) Use of NNRTI at screening (%) On their first NRTI combination PI naïve Hep B Surface Antigen, positive, n (%) Hep C Antibody, positive, n (%) History of IV Drug use DRV/r +2NRTI (n=129) DRV/r (n=127) Multivariate analysis at Week 48 showed that HCV co-infection was highly predictive of response in the primary endpoint. Rieger et al. WAC July 2010, Vienna [abstr TBLBB209]

  5. MONET: HIV RNA by study visit (observed data) HIV RNA>50 copies/mL in 47/1051 samples (4.5%) HIV RNA>50 copies/mL in 69/1009 samples (6.9%) DRV/r + 2 NRTIs DRV/r >1000 copies/ml 400-1000 copies/ml 50-400 copies/ml <50 copies/ml n = 129 115 118 115 114 127 110 108 108 105 Rieger et al. WAC July 2010, Vienna [abstr TBLBB209]

  6. MONET: HIV RNA <50 copies/mL at Week 96, TLOVR, Switch=failure (ITT population) Switch=failure analysis (TLOVR) Switch included analysis Difference = -5.8% (-16.0%, +4.4%)* Difference = +1.4% (-5.5%, +8.3%)* 100 92.1% 90.7% 90 80.6% 74.8% 80 HIV RNA <50 by Week 96 (%) 70 60 50 40 30 20 10 0 DRV/r + 2NRTI DRV/r mono DRV/r + 2NRTI DRV/r mono n=129 n=127 n=129 n=127 * 95% confidence intervals from univariate analysis Rieger et al. WAC July 2010, Vienna [abstr TBLBB209]

  7. MONET: Predictors of 96 week endpoint HIV RNA <50, TLOVR, Per Protocol, Switch=failure Odds ratio (95% confidence intervals) for treatment failure (n.s.: not significant) Rieger et al. WAC July 2010, Vienna [abstr TBLBB209]

  8. MONET trial: one patient in each treatment arm with genotypic PI mutations during the trial DRV/r + 2NRTI Week 24 genotype shows M184V + PI mutations: I54V, V82T, L90M Pre-screening genotype shows M184V + PI mutations: V82I, L90M Week 12 genotype shows DRV RAM: L33F DRV/r mono No pre-screening genotype available Both patient have HIV RNA <50 copies/mL on long-term follow up, with no change in treatment

  9. MONET: Clinical Adverse Events Rieger et al. WAC July 2010, Vienna [abstr TBLBB209]

  10. MONET Week 96: Conclusions • In the primary efficacy analysis at Week 96, rates of double HIV RNA blips and discontinuations were slightly higher in the DRV/r monotherapy arm, compared with the DRV/r + 2NRTI arm. • Most elevations in HIV RNA were low level (50-200 copies/mL), and patients were re-suppressed <50 copies/mL at Week 96, either on the original randomised treatment or with intensified treatment. • Non-inferiority was shown in the “Switch Included” analysis. • HCV co-infection and IV drug use were highly correlated with the primary endpoint. • There were no patients with phenotypic resistance to darunavir during the trial – one patient per arm showed at least one genotypic PI mutation. Rieger et al. WAC July 2010, Vienna [abstr TBLBB209]

  11. Acknowledgments – thanks to the patients and investigators who participated in the trial Rieger et al. WAC July 2010, Vienna [abstr TBLBB209]

More Related